Fosamax (alendronate) to be promoted to PREVENT osteoporosis in postmenopausal women
The FDA will soon allow Fosamax (alendronate) to be promoted to prevent osteoporosis in postmenopausal women.
So far it's approved only for treatment.
Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.